854107-55-4

• 常用中文名：Ponesimod
• 常用英文名：Ponesimod
• CAS号：854107-55-4
• 分子式：C₂₃H₂₅ClN₂O₄S
• 分子量：460.974
• 相关类别： 信号通路 G 蛋白偶联受体/G 蛋白 LPL受体
• 发布时间：2017-04-26 12:25:59
• 更新时间：2026-07-06 20:31:45
• Ponesimod(ACT-128800)是S1P1受体选择性口服型激动剂。

名称

• 中文名: Ponesimod
• 英文名: (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one
• 中文别名: PONESIMOD,SPHINGOSINE-1-PHOPHATE RECTOR激动剂; PONESIMOD,磷酸鞘氨醇受体激动剂; 珀奈莫德(; (2Z,5Z)-5-(3-氯-4-((R)-2,3-二羟基丙氧基)亚苄基)-2-(丙亚胺基)-3-(邻甲苯基)噻唑烷-4-酮; Ponesimod(已纯化)批次6
• 英文别名: 5-[3-Chloro-4-[((2R)-2,3-dihydroxypropyl)oxy]benz-(Z)-ylidene]-2-((Z)-propylimino)-3-(o-tolyl)thiazolidin-4-one; UNII-5G7AKV2MKP; Ponesimod, 10 mM in DMSO; PonesiMod; (2Z,5Z)-5-{3-Chloro-4-[(2R)-2,3-dihydroxypropoxy]benzylidene}-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one; ACT128800;ACT 128800;ACT-128800; S1P1,Lysophospholipid Rector,inflammation,LPL Rector,Ponesimod,Inhibitor,inhibit,lymphocyte-mediated,ACT 128800,ACT; Ponesimod, sphingosine-1-phophate rector agonist; (Z)-5-((Z)-3-Chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one; PONESIMOD,ACT-128800; (2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-(O-TOLYL)THIAZOLIDIN; 4-Thiazolidinone, 5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]Methylene]-3-(2-Methylphenyl)-2-(propyliMino)-, (2Z,5Z); (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propyliMino)-3-(o-tolyl)thiazolidin-4-one; ACT-128800

物化性质

• 密度: 1.3±0.1 g/cm3
• 沸点: 658.0±65.0 °C at 760 mmHg
• 分子式: C₂₃H₂₅ClN₂O₄S
• 分子量: 460.974
• 闪点: 351.7±34.3 °C
• 精确质量: 460.122345
• PSA: 107.66000
• LogP: 5.08
• 外观性状: 粉末
• 蒸汽压: 0.0±2.1 mmHg at 25°C
• 折射率: 1.619
• 储存条件: -20℃

生物活性

• 描述: Ponesimod(ACT-128800)是S1P1受体选择性口服型激动剂。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> LPL受体
  研究领域 >> 炎症/免疫
• 参考文献:

  [1]. Piali L, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337(2):547-56.

  [2]. Bolli MH, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem. 2010 May 27;53(10):4198-211.

  [3]. Brossard P, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013 Dec;76(6):888-96.